The Institute of Cancer Research

(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has uncovered a promising new treatment target for pancreatic cancer, identifying the protein SPP1 as a driver of tumour spread and poor survival. In studies using tumour samples, organoids, and animal models, … Read the full press release →

(IN BRIEF) Scientists at the Institute of Cancer Research, London, together with colleagues from TUD Dresden University of Technology, have discovered that oxidation of a single site in the protein p21 acts as a chemical switch determining whether cells keep … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research and Queen Mary University have created EIRAs, a computational assay that predicts how bowel cancer cells evolve resistance to chemotherapy. By monitoring cell populations and applying evolutionary models, the tool differentiates … Read the full press release →

(IN BRIEF) The largest study to date on testicular germ cell tumours (TGCTs) has revealed a potential link between testicular cancer risk and rare genetic variants affecting cellular movement and structure. Conducted by The Institute of Cancer Research, London, the … Read the full press release →

(IN BRIEF) A landmark international study has provided robust evidence that elevated levels of prolactin, a hormone involved in breast development, increase the risk of breast cancer in post-menopausal women. Researchers from The Institute of Cancer Research in London, along … Read the full press release →

(IN BRIEF) A groundbreaking AI-powered research platform, POETIC-AI, has been unveiled by scientists from The Institute of Cancer Research, promising to accelerate cancer biomarker discovery. Demonstrated at The Alan Turing Institute’s fifth AI UK conference, the platform integrates diverse clinical … Read the full press release →

(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release →

(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release →

(IN BRIEF) Scientists at the Institute of Cancer Research in London have developed an innovative algorithm named SYLVER, which analyzes data from over 9,300 patients to identify synthetic lethal gene pairs that cancer cells depend on for survival. Unlike previous … Read the full press release →

(IN BRIEF) The University of Liverpool is leading two critical projects focused on decarbonising healthcare. The Greener Trials project, led by Professor Paula Williamson, aims to reduce the carbon footprint of clinical trials through an open science approach, collaborating with … Read the full press release →

(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release →

(IN BRIEF) Researchers from The Institute of Cancer Research, London, and Barts Cancer Institute have discovered how the extracellular matrix (ECM) surrounding tumours influences cancer cells to become aggressive and spread throughout the body. Their study, published in Nature Communications, … Read the full press release →

(IN BRIEF) Loughborough University is showcasing the rich tapestry of mixed heritage experiences through a series of stories shared by staff and students from May 7th to May 28th. Organized by Mixedracefaces, the initiative challenges traditional notions of race and … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for treating estrogen receptor-positive, HER2‑negative locally advanced or metastatic breast cancer with specific genetic alterations. The recommendation follows promising results from … Read the full press release →

(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release →

(IN BRIEF) Aviva and mixed-use developer Socius have been selected as the preferred bidders for the advancement of the London Cancer Hub (LCH), a world-leading district dedicated to cancer research and treatment in Sutton, London. The partnership will collaborate with … Read the full press release →

(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release →